Stroke prothrombin complex

Cardiovascular The main adverse effect of prothrombin complex concentrates is a risk of thrombosis, as patients taking oral anticoagulants have prothrombotic susceptibility factors [31, 33 ]. Reported thromboembolic complications include ischemic stroke, venous thromboembolism (venous thrombosis or pulmonary embolism), myocardial infarction, and disseminated intravascular coagulation [32 ]. [Pg.519]

In 14 clinical trials of prothrombin complex concentrates for reversal of oral anticoagulation therapy, seven of 460 patients (1.5%) had thrombotic events, three thrombotic strokes, two cases of deep venous thrombosis, and two non-Q-wave myocardial infarctions [31 ]. However, in 40 patients taking oral anticoagulants, who needed cardiopulmonary bypass surgery, and of whom 20 were treated with prothrombin complex concentrates, no thrombotic events occurred [35 ]. [Pg.519]

Hematologic Historically, there was concern that prothrombin complex concentrates were associated with thrombotic events such as stroke, myocardial infarction, pulmonary embolism, deep venous thrombosis, and disseminated intravascular coagulation. These events resulted mainly from the use of prothrombin complex concentrates as source of factor IX in patients with hemophilia B, and in particular after surgery, but the reported incidence is low and there is considerable evidence that the risk of thrombosis has been minimized with current prothrombin complex concentrates by reduced use of activated factors and the... [Pg.680]

Switzer JA, Rocker J, Mohorn P, Waller JL, Hughes D, Bruno A, et al. Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage. Stroke 2012 43(9) 2500-2. [Pg.501]